Yuhan Corporation & Samsung Bioepis sign exclusive biosimilar sales agreement
Yuhan Corporation(CEO Jung-Hee Lee) signed an exclusive sales agreement of the Remicade(generic name: infliximab) biosimilar(SB2) and the Enbrel(generic name: etanercept) biosimilar(SB4) in Korea with Samsung Bioepis(CEO Han-Seung Ko).
The Remicade biosimilar(SB2) and the Enbrel biosimilar(SB4) ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
